HIQA’s Report on Repatriating Paediatric Stem Cell Transplants

By HEOR Staff Writer

March 8, 2023

Introduction

The repatriation of paediatric stem cell transplants to Ireland stands as a promise for families affected by rare inherited conditions. This initiative promises to alleviate the emotional and financial strain of seeking treatment abroad, while potentially reducing healthcare expenditures.

Understanding Stem Cell Transplants

Stem cell transplants, particularly allogeneic haematopoietic stem cell transplants (HSCT), are life-saving procedures for children with rare conditions such as metabolic errors and haemoglobinopathies. Currently, these services are sought in the UK, under the HSE’s Treatment Abroad Scheme. However, the repatriation of these services could mean significant changes for patients and the healthcare system.

Analysing the Impact of Repatriating Paediatric Stem Cell Transplants

The Health Information and Quality Authority (HIQA) has published a health technology assessment (HTA) that could redefine paediatric care in Ireland. By potentially doubling the number of transplants conducted domestically, the move could streamline services and reduce costs. Yet, this shift hinges on the successful recruitment of skilled staff and an increase in available beds, particularly with the opening of the new National Children’s Hospital.

The Human Aspect of Healthcare

Beyond the numbers lies the human impact. Families currently face prolonged separations and the stress of foreign travel for treatment. Dr Máirín Ryan of HIQA emphasises the reduction in emotional and logistical burdens that repatriation could bring. Bringing treatment home resonates with the core values of patient-centred care.

The Financial Equation

Cost is a critical factor in healthcare decisions. While uncertainties remain, HIQA’s findings suggest that repatriating care could lead to cost reductions for the HSE. This factor cannot be overlooked, as it implies a more sustainable healthcare model for Ireland’s future. From the perspective of the HSE, while subject to substantial uncertainty, the estimated five-year incremental budget impact is expected to result in cost reductions. Over a five-year time horizon, depending on whether costs arising from ancillary procedures are excluded or included, the reduction is estimated as €2.3 million (95% CI -€5.8m to +€1.1m) or €1.5 million (95% CI -€5.0m to +€1.9m), respectively.

Conclusion

The repatriation of paediatric stem cell transplants represents more than a procedural shift; it signifies a commitment to enhancing the quality of life for families and children. It embodies a strategic move towards a more integrated and compassionate healthcare system in Ireland.

Reference url

Recent Posts

Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Empowering Innovation: Clinical Trials Reform Strategies by EMA for 2025

By João L. Carapinha

September 29, 2025

The recently published European Medicines Agency (EMA) article addresses the strategic targets for improving the clinical trials reform landscape in Europe. It emphasizes measures that foster innovation, collaboration, and efficiency in clinical research. The article outlines new priorities for 2...